Early Phase 1 Pancreatic Cancer Trial, Recruiting NCT04665947 Sponsor: University of California, Davis Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Early Phase 1 Pancreatic Cancer Trial, Recruiting

NCT04665947
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People with a confirmed diagnosis of pancreatic adenocarcinoma (a specific type of pancreatic cancer) that has spread or cannot be surgically removed, and where at least one measurable tumour or affected lymph node is visible on scans
  • People whose cancer has been shown by CT or MRI scan (taken within the past 28 days) to have continued growing or spreading despite at least one prior treatment
  • People with a general health and activity level rated at 2 or below on a standard medical scale, meaning they are able to care for themselves but may not be able to do heavy physical work (confirm with trial site)
  • People who have finished their most recent chemotherapy at least 2 weeks before the first scan, and whose side effects from prior treatment have mostly resolved
  • People with blood cell counts within an acceptable range, as measured by a blood test (confirm with trial site for specific values)
  • People with liver and kidney function within an acceptable range, as measured by a blood test (confirm with trial site for specific values)
  • People with a life expectancy of at least 3 months
  • People who are able to lie still without moving for 30 to 60 minutes during a scan
  • For the treatment phase: people who have already completed the first scan part of the trial, and whose scan shows the cancer is detectable at a level above a set threshold (confirm with trial site)

Who may not be able to join:

  • People currently taking blood-thinning or antiplatelet medications, with the exception of low-dose aspirin
  • People with severe heart failure (classified as Class 3 or 4 on a standard medical scale)
  • People who have had a significant bleed — such as from the stomach, bowel, or brain — within the two weeks before joining the trial
  • People who are pregnant or currently breastfeeding
  • People who have had a major surgical procedure under general anaesthetic within 28 days before the trial starts, or who are expected to need major surgery within 6 weeks of starting
  • People who have another active cancer that has required treatment within the past 2 years
  • People with an active, uncontrolled infection caused by bacteria, a virus, or fungus that requires ongoing treatment
  • People whose mental health or personal circumstances would make it difficult to follow the trial requirements
  • People who have previously had radiation therapy for advanced or metastatic disease
  • People who weigh more than 350 pounds (approximately 159 kg), as the scanning equipment has a weight limit
  • People whose blood clotting levels fall outside the acceptable range set by the trial (confirm with trial site for specific values)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: Julie L Sutcliffe, University of California, Davis

Phone: 916-734-5536

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Registry
ClinicalTrials.gov
Start date
18 December 2020
Est. completion
31 July 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

[68Ga]Ga DOTA-5G PET/CT imaging; [177Lu]Lu DOTA-ABM-5G dose escalation therapy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov